ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年06月09日 10時00分
Source:
Eisai
エーザイ、2023年3月期業績予想(IFRS)の修正に関するお知らせ
東京, 2022年06月09日 - (JCN Newswire) - 直近の業績の動向等を踏まえ、2022年5月13日に公表した2023年3月期(2022年4月1日から2023年3月31日)の業績予想を下記のとおり修正しますのでお知らせします。
1. 2023年3月期の連結業績予想数値の修正(2022年4月1日から2023年3月31日)
※ご参照
https://www.eisai.co.jp/news/2022/news202246.html
2. 修正の理由
当期において、当社が保有する一部株式について株式譲渡益10億円が発生する見込みです。加えて、当社の資本政策の一環としてグローバルな資金配分の最適化を企図し、米国の連結子会社から資金を回収するために当社が米国子会社から払込資本の払戻しを受けた結果、税務上の譲渡損失等が当社にて発生し、法人所得税が従来の想定を下回ることを見込んでいます。これらにより、当期利益を前回予想から115億円増の580億円、親会社の所有者に帰属する当期利益を前回予想から115億円増の570億円に修正します。ROE(親会社所有者帰属持分当期利益率)は7.5%を見込みます。
売上収益、営業利益については、前回予想から変更ありません。
なお、1株当たり160円の年間配当金(第2四半期末80円、期末80円)の予定に変更はありません。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202246.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
NEC develops robot control technology using AI to achieve safe, efficient autonomous movement even at sites with many obstacles
Aug 21, 2025 10:39 JST
Hengdeli Announces 2025 Interim Results
Aug 20, 2025 20:52 JST
Honda Establishes New Subsidiary in India for Retail Financing Services
Aug 20, 2025 18:15 JST
Sharp Introduces Conversational AI Character "Poketomo"
Aug 20, 2025 16:22 JST
Collaborate with BNI, JCB Launch the 1st JCB Corporate Card in Indonesia
Aug 20, 2025 16:00 JST
NEC collaborates with WFP to strengthen cooperative development in Africa
Aug 20, 2025 15:53 JST
Hitachi High-Tech and NOF Metal Coatings use materials informatics to improve the efficiency and sophistication of research and development work
Aug 19, 2025 16:38 JST
NEC and ClimateAi Develop Conceptual Model to Promote Climate Change Adaptation in Agriculture
Aug 19, 2025 11:33 JST
Value Research Center to host The Valuism Conference 2025 on August 28-29 (Hybrid Format)
Aug 19, 2025 11:00 JST
Fujitsu signs new licensing agreement with Palantir
Aug 19, 2025 10:55 JST
The 35th Food Expo and concurrent fairs attract over 500,000 visits
Aug 18, 2025 21:07 JST
Team Mitsubishi Ralliart Triumphs at Asia Cross Country Rally 2025 with Chayapon Yotha's Overall Victory and Team Award
Aug 18, 2025 15:22 JST
UNFPA and NEC Collaborate to Build Beneficiary Information Management and e-Voucher System
Aug 18, 2025 14:38 JST
Anime Tokyo Station Surpasses 200,000 Visitors
Aug 18, 2025 11:00 JST
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Aug 18, 2025 09:11 JST
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 03:00 JST
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
Team Mitsubishi Ralliart Conducts Shakedown Ahead of Asia Cross Country Rally 2025: Targeting First Overall Championship in Three Years
Aug 07, 2025 18:40 JST
Toyota to Establish New Vehicle Manufacturing Plant in Japan
Aug 07, 2025 18:31 JST
MHI Heat Pumps NZ Wins People's Choice Award for Third Year Running
Aug 07, 2025 17:32 JST
More Latest Release >>
Related Release
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
8/18/2025 9:11:00 AM JST
Revenue of LEQEMBI(R) (Preliminary Basis)
7/31/2025 6:27:00 PM JST
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
7/31/2025 9:30:00 AM JST
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
7/31/2025 9:20:00 AM JST
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
7/31/2025 9:10:00 AM JST
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
7/29/2025 9:01:00 AM JST
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
7/25/2025 1:31:00 PM JST
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
7/23/2025 10:07:00 AM JST
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
7/22/2025 11:56:00 AM JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
More Press release >>